

Reference number(s)
3205-H

## SPECIALTY QUANTITY LIMIT PROGRAM

### ESBRIET (pirfenidone)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of idiopathic pulmonary fibrosis fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Esbriet (pirfenidone) capsules 267 mg	270 per 30 days	Idiopathic pulmonary fibrosis: Days 1 through 7: 267 mg (one 267 mg capsule/tablet) three times daily (801 mg/day)
Esbriet (pirfenidone) tablets 267 mg	270 per 30 days	Days 8 through 14: 534 mg (two 267 mg capsules/tablets) three times daily (1602 mg/day)
Esbriet (pirfenidone) tablets 801 mg	90 per 30 days	Days 15 onward: 801 mg (three 267 mg capsules/tablets or one 801 mg tablet) three times daily (2403 mg/day)

#### III. REFERENCES

1. Esbriet [package insert]. South San Francisco, CA: Genentech USA, Inc.; October 2017.